Japan’s Shionogi Seen Defending Self Against Takeover With Sciele Buy
This article was originally published in PharmAsia News
Executive Summary
The acquisition by Japan's Shionogi of U.S. drug maker Sciele Pharma is seen as an attempt to protect itself from being an acquisition target because of its attractive drug pipeline. Isao Teshirogi, Shionogi president, emphasizes the firm's acquisition of a U.S. sales network, but the firm had resisted that move in the past. The company may have changed its attitude when it began to see progress in developing new drug candidates to treat major problems such as obesity and HIV raising its profile and making it a takeover target in the eyes of Western drug makers. (Click here for more - a subscription may be required